- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01045044
Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy
4. april 2012 opdateret af: Kettering Health Network
Magnetic Resonance Imaging of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Anthracycline-based Systemic Chemotherapy
We will use magnetic resonance imaging (MRI) to investigate tumor changes in women with breast cancer who are receiving anthracycline-based systemic chemotherapy.
We will also use MRI and cognitive tests to study the possible effects of chemotherapy on the brains of these women.
The results will be compared to a control group of normal healthy women.
We will try to determine if MRI can be used to predict tumor response and cognitive changes related to the chemotherapy.
Studieoversigt
Status
Trukket tilbage
Betingelser
Detaljeret beskrivelse
In this work we will utilize conventional magnetic resonance imaging as well as a set of advanced magnetic resonance imaging tools to investigate changes in tumor physiology and the human brain resulting from anthracycline-based systemic chemotherapy.
We will recruit up to 15 subjects diagnosed with breast cancer and preparing for an anthracycline-based systemic chemotherapy regimen.
Each subject will undergo the set of MR imaging tools before therapy, after one therapy session, after four therapy sessions, and at the conclusion of therapy.
Conventional MRI methods will be used to quantify tumor-response to chemotherapy for each subject.
A control group of up to 15 normal subjects will also be recruited and will undergo MR brain imaging twice with a gap of 6 months between scans.
All subjects will also undergo a battery of neuropsychological tests at each imaging session.
The results of the neuropsychological tests will be used to quantify cognitive changes for each subject.
A final analysis will determine if the advanced MR modalities can be used to predict the response of tumors or human cognition to chemotherapy.
Undersøgelsestype
Observationel
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Ohio
-
Dayton, Ohio, Forenede Stater, 45408
- Medical Oncology Hematology Associates, Inc
-
Kettering, Ohio, Forenede Stater, 45429
- Innovation Center, Kettering Health Network
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Kvinde
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Breast cancer cohort will be patients of Medical Oncology Hematology Associates Inc., Dayton, OH
Normal controls will be recruited from Kettering College of Medical Arts and the Kettering Health Network.
Beskrivelse
Inclusion Criteria:
- Diagnosed with Adenocarcinoma(ER+ve, PR+ve)
- Prescribed, but not yet begun, anthracycline based systemic chemotherapy
- Not prescribed Avastin
- Able to read and write in English
- Have signed informed consent
Exclusion Criteria:
- Diagnosed psychiatric disorder
- Conditions that would preclude MRI (Pacemaker, metal objects in body, claustrophobia, pregnancy, etc.)
- Serious, unstable medical or mental illness
- Medical contraindication to any study procedure
- Current alcohol or other substance use disorder (excluding nicotine)
- Have not read and signed informed consent, or do not understand its contents
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Breast cancer, chemotherapy
Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
|
|
Normal control
Up to 15 normal, healthy women.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Jason Parker, PhD, Kettering Health Network
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2009
Primær færdiggørelse (Faktiske)
1. oktober 2011
Studieafslutning (Faktiske)
1. oktober 2011
Datoer for studieregistrering
Først indsendt
6. januar 2010
Først indsendt, der opfyldte QC-kriterier
7. januar 2010
Først opslået (Skøn)
8. januar 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
5. april 2012
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
4. april 2012
Sidst verificeret
1. april 2012
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- KHNIC-P09-004
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Brystkræft
-
Cairo UniversityIkke rekrutterer endnu
-
The First Affiliated Hospital of Xiamen UniversityIkke rekrutterer endnuLocally Advanced Breast Cancer (LABC)
-
Abouqir General HospitalAlexandria UniversityRekrutteringBreast Udseende Rekonstruktion DisproportionEgypten
-
Beijing Bio-Targeting Therapeutics Technology Co...Trukket tilbage
-
Indonesia UniversityIkke rekrutterer endnuPræhabilitering | Postoperativ inflammation | Locally Advanced Breast Cancer (LABC)Indonesien
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbejdspartnereAfsluttetDen kliniske anvendelsesvejledning af Conebeam Breast CTKina
-
Atlas UniversityIkke rekrutterer endnuBrystkræft | Locally Advanced Breast Cancer (LABC)Tyrkiet (Türkiye)
-
ETOP IBCSG Partners FoundationAfsluttetBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAfsluttetBreast Cancer Invasive NosSpanien
-
Second Affiliated Hospital, School of Medicine,...RekrutteringTNBC, Triple Negative Breast CancerKina